A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

NCT05218902 · clinicaltrials.gov ↗

COMPLETED

Status

290

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic
Leukemia, Myeloid, Acute

Sponsor

Bristol-Myers Squibb